|
|
|
Volumn 67, Issue 17, 2007, Pages 2656-
|
|
Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Barbara Wassmann.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
IMATINIB;
PIPERAZINE DERIVATIVE;
PYRIMIDINE DERIVATIVE;
ARTICLE;
DISEASE COURSE;
DRUG RESISTANCE;
DRUG TOXICITY;
GENETICS;
HUMAN;
LYMPHATIC LEUKEMIA;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHILADELPHIA 1 CHROMOSOME;
POINT MUTATION;
RECURRENT DISEASE;
SALVAGE THERAPY;
SURVIVAL RATE;
TREATMENT OUTCOME;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CLINICAL TRIALS, PHASE I AS TOPIC;
CLINICAL TRIALS, PHASE II AS TOPIC;
DISEASE PROGRESSION;
DRUG RESISTANCE, NEOPLASM;
DRUG TOXICITY;
HUMANS;
PHILADELPHIA CHROMOSOME;
PIPERAZINES;
POINT MUTATION;
PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;
PYRIMIDINES;
RECURRENCE;
SALVAGE THERAPY;
SURVIVAL RATE;
TREATMENT OUTCOME;
|
|
EID: 38749153633
PISSN: 00126667
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (1)
|
|
References (0)
|
